-
Combination of chemotherapy and all-trans retinoic acid for the treatment KMT2A-rearranged infant acute lymphoblastic leukemia. Results of the MLL-Baby trial Leukemia (IF 11.4) Pub Date : 2023-09-23 Larisa Fechina, Alexander Popov, Grigory Tsaur, Guenter Henze, Egor Shorikov, Olga Makarova, Olga Khlebnikova, Yulia Zhukova, Oleg Arakaev, Olga Streneva, Tatiana Verzhbitskaya, Tatiana Riger, Alexander Solodovnikov, Elena Lapotentova, Olga Aleinikova, Natalia Myakova, Elmira Boichenko, Konstantin Kondratchik, Olga Nikonova, Alexander Shapochnik, Marina Goroshkova, Natalia Ponomareva, Galina Novichkova
-
The acidic stretch and the C-terminal nuclear export signal motif of NPM1 mutant: are they druggable in AML? Leukemia (IF 11.4) Pub Date : 2023-09-22 Brunangelo Falini, Bjorn T. Gjertsen, Vibeke Andresen
-
Histone deacetylase inhibitors modulate hormesis in leukemic cells with mutant FMS-like tyrosine kinase-3 Leukemia (IF 11.4) Pub Date : 2023-09-21 Yanira Zeyn, Kristin Hausmann, Melisa Halilovic, Mandy Beyer, Hany S. Ibrahim, Walburgis Brenner, Siavosh Mahboobi, Matthias Bros, Wolfgang Sippl, Oliver H. Krämer
-
Mast cell cytomorphology and treatment outcome in mast cell leukemia Am. J. Hematol. (IF 12.8) Pub Date : 2023-09-21 Ayalew Tefferi, Animesh Pardanani, Aref Al-Kali, Hassan Alkhateeb, Kristen McCullough, Mrinal Patnaik, William J. Hogan, Kebede Begna, Michelle A. Elliott, Nandita Khera, Jeanne M. Palmer, Naseema Gangat, Katalin Kelemen, Attilio Orazi, Dong Chen, Kaaren K. Reichard
Systemic mastocytosis (SM) in adults almost always involves the bone marrow (BM) and less frequently, the skin and other organs, including the liver, spleen, and bones.1 The extent of neoplastic mast cell (MC) proliferation (i.e., MC burden), MC-associated organopathy, and co-occurrence of an associated myeloid neoplasm (AMN) determine disease severity and allow subclassification into indolent SM (ISM)
-
Successful cord blood transplantation for del7q myelodysplastic syndrome in Pearson marrow pancreas syndrome Am. J. Hematol. (IF 12.8) Pub Date : 2023-09-21 Zacharia H. Belgacem, Sonia M. Dubois, Elad Jacoby, Paul L. Martin, Sumit B. Parikh, Mark D. Fleming, Suneet Agarwal
Pearson marrow pancreas syndrome (PS) is a multisystem bone marrow failure (BMF) disorder caused by deletions in mitochondrial DNA (mtDNA). Infant-onset transfusion-dependent pancytopenia, immune defects, and metabolic crises result in early mortality. However, PS often goes undiagnosed, and its rarity, comorbidities, and occasional spontaneous hematologic improvement deter timely consideration of
-
Comparison of the prognostic predictive value of Molecular International Prognostic Scoring System and Revised International Prognostic Scoring System in patients undergoing allogeneic hematopoietic stem cell transplantation for myelodysplastic neoplasms Am. J. Hematol. (IF 12.8) Pub Date : 2023-09-20 Tingting Yang, Binqian Jiang, Yi Luo, Yanmin Zhao, Guifang Ouyang, Jian Yu, Jianping Lan, Ying Lu, Xiaoyu Lai, Baodong Ye, Yi Chen, Lizhen Liu, Yang Xu, Pengfei Shi, Haowen Xiao, Huixian Hu, Qunyi Guo, Huarui Fu, Yishan Ye, Xinyu Wang, Jie Sun, Weiyan Zheng, Jingsong He, Yi Zhao, Wenjun Wu, Zhen Cai, Guoqing Wei, He Huang, Jimin Shi
Myelodysplastic neoplasms (MDS) are heterogeneous clonal hematopoietic neoplasms with a high risk of evolution into acute myeloid leukemia.1 Given the highly variable clinical courses of MDS, the importance of risk stratification for distinguishing high-risk patients has been underscored.2 Currently, the most widely used survival prediction models are the International Prognostic Scoring System (IPSS)
-
Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial Leukemia (IF 11.4) Pub Date : 2023-09-21 A. S. Kubasch, P. Peterlin, T. Cluzeau, K. S. Götze, K. Sockel, R. Teipel, M. Jentzsch, H. Attalah, M. Sebert, F. Chermat, S. Gloaguen, M. Puttrich, M. Cross, M. Schneider, S. Kayser, D. Schipp, A. Giagounidis, I. Tirado-Gonzalez, A. Descot, A. van de Loosdrecht, A. Weigert, K. H. Metzeler, P. Fenaux, H. Medyouf, U. Platzbecker, L. Ades
-
U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity Blood Cancer J. (IF 12.8) Pub Date : 2023-09-21 Talha Badar, Yenny A. Moreno Vanegas, Ahmad Nanaa, James M. Foran, Aref Al-Kali, Abhishek Mangaonkar, Hemant Murthy, Hassan B. Alkhateeb, David Viswanatha, Rong He, Mithun Shah, Cecilia Arana Yi, Mark R. Litzow, Naseema Gangat, Ayalew Tefferi, Mrinal M. Patnaik
-
Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents Blood Cancer J. (IF 12.8) Pub Date : 2023-09-21 Danielle Hammond, Sanam Loghavi, Sa A. Wang, Marina Y. Konopleva, Tapan M. Kadia, Naval G. Daver, Maro Ohanian, Ghayas C. Issa, Yesid Alvarado, Nicholas J. Short, Koji Sasaki, Naveen Pemmaraju, Guillermo Montalban-Bravo, Curtis A. Lachowiez, Abhishek Maiti, Guillermo Garcia-Manero, Elias J. Jabbour, Gautam Borthakur, Farhad Ravandi, Koichi Takahashi, Sherry R. Pierce, Hagop M. Kantarjian, Courtney
-
Clinical phenotypes, molecular analysis, and outcomes of patients with Rosai-Dorfman disease Leukemia (IF 11.4) Pub Date : 2023-09-20 Long Chang, Bing Qiao, Hao Cai, He Lin, Ming-hui Duan, Jian Li, Dao-bin Zhou, Gaurav Goyal, Chun-yan Sun, Xin-xin Cao
-
Survival with chronic myeloid leukaemia after failing milestones Leukemia (IF 11.4) Pub Date : 2023-09-19 Michael Lauseker, Rüdiger Hehlmann, Andreas Hochhaus, Susanne Saußele
-
In-class transition (iCT) of proteasome inhibitor-based therapy: a community approach to multiple myeloma management Blood Cancer J. (IF 12.8) Pub Date : 2023-09-19 Robert M. Rifkin, Saulius K. Girnius, Stephen J. Noga, Ruemu E. Birhiray, Suman Kambhampati, Sudhir Manda, Roger M. Lyons, Habte A. Yimer, Dasha Cherepanov, Eric Lloyd, Presley Whidden, Joshua Richter
-
Correction: Human CD34+ very small embryonic-like stem cells can give rise to endothelial colony-forming cells with a multistep differentiation strategy using UM171 and nicotinamide acid Leukemia (IF 11.4) Pub Date : 2023-09-18 Alison Domingues, Elisa Rossi, Kamila Bujko, Grégoire Detriche, Ulysse Richez, Adeline Blandinieres, Magdalena Kucia, Janina Ratajczak, David M. Smadja, Mariusz Z. Ratajczak
-
Identification of novel genetic loci for risk of multiple myeloma by functional annotation Leukemia (IF 11.4) Pub Date : 2023-09-18 Angelica Macauda, Klara Briem, Alyssa Clay-Gilmour, Wendy Cozen, Asta Försti, Matteo Giaccherini, Chiara Corradi, Juan Sainz, Yasmeen Niazi, Rob ter Horst, Yang Li, Mihai G. Netea, Ulla Vogel, Kari Hemminki, Susan L. Slager, Judit Varkonyi, Vibeke Andersen, Elzbieta Iskierka-Jazdzewska, Joaquin Mártinez-Lopez, Jan Zaucha, Nicola J. Camp, S. Vincent Rajkumar, Agnieszka Druzd-Sitek, Parveen Bhatti, Stephen
-
Eltrombopag with or without Tacrolimus for relapsed/refractory acquired aplastic anaemia: a prospective randomized trial Blood Cancer J. (IF 12.8) Pub Date : 2023-09-19 Jiang Ji, Ziqi Wan, Jing Ruan, Yuan Yang, Qinglin Hu, Zesong Chen, Chen Yang, Miao Chen, Bing Han
-
Bone marrow fibrosis is associated with non-response to CD19 CAR T-cell therapy in B-acute lymphoblastic leukemia Am. J. Hematol. (IF 12.8) Pub Date : 2023-09-18 Joshua Anil, Ahab Alnemri, Andrew Lytle, Brian Lockhart, Ashley E. Anil, Michael Baumgartner, Kirubel Gebre, Jared McFerran, Stephan A. Grupp, Susan R. Rheingold, Vinodh Pillai
CD19 directed CAR T-cell therapy is used to treat relapsed/refractory B-cell acute lymphoblastic leukemia. The role of the pre-CAR bone marrow (BM) stromal microenvironment in determining response to CAR T-cell therapy has been understudied. We performed whole transcriptome analysis, reticulin fibrosis assessment and CD3 T-cell infiltration on BM core biopsies from pre- and post-CAR timepoints for
-
Severe cutaneous necrosis in antiphospholipid syndrome Am. J. Hematol. (IF 12.8) Pub Date : 2023-09-15 Mariam Mostafa, Amir Mahmoud, Hebat-Allah Egiza, Chengu Niu, Mohamed Elbahnasawy, Yasmin Yusuf, Peter Kouides
Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by recurrent thrombosis and/or recurrent fetal loss. APS can be primary or secondary to autoimmune disorders such as systemic lupus erythematosus (SLE). It is unique from other thrombophilic disorders in that it predisposes patients to not only venous but also arterial thrombosis through endothelial cell damage and activation
-
Chronic GvHD in a prognostic model: Graft versus leukemia predictor or immortal time bias? Am. J. Hematol. (IF 12.8) Pub Date : 2023-09-15 Erik G. J. von Asmuth, Arjan C. Lankester, Hein Putter
Zhou et al. recently published a prognostic model for patients with chronic myelomonocytic leukemia (CMML) undergoing allogeneic hematopoietic stem cell transplantation (HSCT) in this journal.1 This score consisted of five items: Age, Blasts, Leukocytes, Anemia, and chronic Graft vs Host Disease (ABLAG). The strongest predictor in this score was the absence of chronic Graft vs Host Disease (cGvHD)
-
Germline DDX41 mutant predisposition syndromes: Slow driver states to hematological malignancies Am. J. Hematol. (IF 12.8) Pub Date : 2023-09-13 Timothy M. Chlon, Mrinal M. Patnaik
CONFLICT OF INTEREST STATEMENT Mrinal M Patnaik has received research funding from StemLine Pharmaceuticals, Kura Oncology, and Epigenetix. He has served on the advisory board for CTI pharmaceuticals.
-
Immunomodulatory cytokines and clonal dynamics in low-risk myelodysplastic syndromes patients treated with luspatercept Am. J. Hematol. (IF 12.8) Pub Date : 2023-09-12 Bruno Fattizzo, Alfredo Marchetti, Anna Zaninoni, Marta Lionetti, Marta Riva, Lorenzo Rizzo, Loredana Pettine, Nicole Galli, Federico Mazzon, Elisa Fermo, Akihiro Maeda, Alessio Marella, Matteo Claudio Da Vià, Francesco Passamonti, Niccolò Bolli, Wilma Barcellini
Myelodysplastic neoplasms (MDS) with ring sideroblasts represent about 30% of all MDS patients and are characterized by severe anemia, transfusion dependence, and limited response to erythropoiesis stimulating agents (ESAs). Most patients harbor a somatic mutation of Splicing Factor 3B1 (SF3B1),1 whose presence identifies a distinct entity in the fifth edition of the WHO classification of myeloid neoplasms
-
Persistence of ex vivo expanded tumour and pathogen specific T-cells after allogeneic stem cell transplant for myeloid malignancies (the INTACT study) Leukemia (IF 11.4) Pub Date : 2023-09-15 Wei Jiang, Selmir Avdic, Koon H. Lee, Janine Street, Gloria Castellano-González, Renee Simms, Leighton E. Clancy, Richard Blennerhassett, Ellis Patrick, Adam S. Chan, Helen M. McGuire, Nadav Myers, Brian S. Gloss, Melissa Gabriel, Caroline M. Bateman, Ken Micklethwaite, David J. Gottlieb, Emily Blyth
-
A novel gene fusion RUNX1/ZNF423 promotes leukemic relapse of NUP98-rearranged AML Leukemia (IF 11.4) Pub Date : 2023-09-15 Wenxin Du, Zhimei Xia, Zebin Luo, Yichang Chen, Shaowei Bing, Wei Wang, Xingya Zhang, Zhan Zhou, Jingying Zhang, Ji Cao, Bo Yang, Qiaojun He, Xuejing Shao, Xiaojun Xu, Meidan Ying
-
Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial Lancet Haematol. (IF 24.7) Pub Date : 2023-09-11 Peter M Voorhees, Douglas W Sborov, Jacob Laubach, Jonathan L Kaufman, Brandi Reeves, Cesar Rodriguez, Ajai Chari, Rebecca Silbermann, Luciano J Costa, Larry D Anderson, Nitya Nathwani, Nina Shah, Naresh Bumma, Yvonne A Efebera, Sarah A Holstein, Caitlin Costello, Andrzej Jakubowiak, Tanya M Wildes, Robert Z Orlowski, Kenneth H Shain, Paul G Richardson
Background Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (D-RVd) in the GRIFFIN study improved the stringent complete response rate by the end of consolidation in transplantation-eligible patients with newly diagnosed multiple myeloma. Here, we report the findings of the predefined final analysis. Methods GRIFFIN was an open-label, randomised, active-controlled, phase 2 trial
-
Targeted dosing of anti-thymocyte globulin in adult unmanipulated haploidentical peripheral blood stem cell transplantation: A single-arm, phase 2 trial Am. J. Hematol. (IF 12.8) Pub Date : 2023-09-14 Haitao Wang, Nan Wang, Lili Wang, Jishan Du, Fei Li, Yangliu Shao, Bo Peng, Songhua Luan, Lu Wang, Xiangshu Jin, Chunji Gao, Liping Dou, Daihong Liu
-
Drivers of deep molecular response and long-term outcomes in patients with core binding factor acute myeloid leukemia Am. J. Hematol. (IF 12.8) Pub Date : 2023-09-13 Parth C. Patel, Somedeb Ball, Akriti G. Jain, Chen Wang, Mohammad O. Hussaini, Luis E. Aguirre, Onyee Chan, Seongseok Yun, Andrew Kuykendall, Eric Padron, Kendra Sweet, Jeffrey E. Lancet, Rami S. Komrokji, David A. Sallman
-
Ppm1d truncating mutations promote the development of genotoxic stress-induced AML Leukemia (IF 11.4) Pub Date : 2023-09-14 Monika Burocziova, Petr Danek, Anna Oravetzova, Zuzana Chalupova, Meritxell Alberich-Jorda, Libor Macurek
-
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib Blood Cancer J. (IF 12.8) Pub Date : 2023-09-11 Chung H. Kok, Verity A. Saunders, Phuong Dang, Naranie Shanmuganathan, Deborah White, Susan Branford, David Yeung, Timothy P. Hughes
-
Have we been qualifying measurable residual disease correctly? Leukemia (IF 11.4) Pub Date : 2023-09-13 Yahui Feng, Saibing Qi, Xueou Liu, Li Zhang, Yu Hu, Qiujin Shen, Xiaowen Gong, Wei Zhang, Junxia Wang, Wen Yan, Tiantian Wang, Huijun Wang, Zhen Song, Xiaofan Zhu, Robert Peter Gale, Junren Chen
-
CD7 targeted “off-the-shelf” CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies Leukemia (IF 11.4) Pub Date : 2023-09-12 Shiqi Li, Xinxin Wang, Lin Liu, Jia Liu, Jun Rao, Zhongtao Yuan, Li Gao, Yu Li, Le Luo, Gui Li, Zhimin Li, Sheng Li, Jiaping He, Lihua Zhang, Lvzhe Chen, Wenhui Huang, Ping Yin, Chunmin Li, Xiaoping Li, Youcheng Wang, Yancheng Dong, Dingsong Zhang, Qingying Zang, Yingnian Chen, Lianjun Shen, Wenling Li, Wei Cao, Xi Zhang, Sanbin Wang
-
Identification of DHX40 as a candidate susceptibility gene for colorectal and hematological neoplasia Leukemia (IF 11.4) Pub Date : 2023-09-11 Alisa Olkinuora, Taina T. Nieminen, Suvi Douglas, Anni Kauppinen, Mika Kontro, Juho Väänänen, Matti Kankainen, Ari Ristimäki, Markus Mäkinen, Päivi Lahermo, Caroline Heckman, Janna Saarela, Milla Salonen, Anna Lepistö, Heikki Järvinen, Jukka-Pekka Mecklin, Outi Kilpivaara, Ulla Wartiovaara-Kautto, Kimmo Porkka, Päivi Peltomäki
-
Genomic profiling of post-transplant lymphoproliferative disorders using cell-free DNA J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-09-14 Nick Veltmaat, Yujie Zhong, Filipe Montes de Jesus, Geok Wee Tan, Johanna A. A. Bult, Martijn M. Terpstra, Pim G. N. J. Mutsaers, Wendy B. C. Stevens, Rogier Mous, Joost S. P. Vermaat, Martine E. D. Chamuleau, Walter Noordzij, Erik A. M. Verschuuren, Klaas Kok, Joost L. Kluiver, Arjan Diepstra, Wouter J. Plattel, Anke van den Berg, Marcel Nijland
Diagnosing post-transplant lymphoproliferative disorder (PTLD) is challenging and often requires invasive procedures. Analyses of cell-free DNA (cfDNA) isolated from plasma is minimally invasive and highly effective for genomic profiling of tumors. We studied the feasibility of using cfDNA to profile PTLD and explore its potential to serve as a screening tool. We included seventeen patients with monomorphic
-
Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-09-12 Hao-Ran Jin, Jin Wang, Zi-Jing Wang, Ming-Jia Xi, Bi-Han Xia, Kai Deng, Jin-Lin Yang
Lipid metabolic reprogramming is an emerging hallmark of cancer. In order to sustain uncontrolled proliferation and survive in unfavorable environments that lack oxygen and nutrients, tumor cells undergo metabolic transformations to exploit various ways of acquiring lipid and increasing lipid oxidation. In addition, stromal cells and immune cells in the tumor microenvironment also undergo lipid metabolic
-
Treatment of older adults with FLT3-mutated AML: Emerging paradigms and the role of frontline FLT3 inhibitors Blood Cancer J. (IF 12.8) Pub Date : 2023-09-11 Nicholas J. Short, Daniel Nguyen, Farhad Ravandi
-
Identifying novel mechanisms of biallelic TP53 loss refines poor outcome for patients with multiple myeloma Blood Cancer J. (IF 12.8) Pub Date : 2023-09-11 Enze Liu, Parvathi Sudha, Nathan Becker, Oumaima Jaouadi, Attaya Suvannasankha, Kelvin Lee, Rafat Abonour, Mohammad Abu Zaid, Brian A. Walker
-
Zanubrutinib: past, present, and future Blood Cancer J. (IF 12.8) Pub Date : 2023-09-11 Constantine S. Tam, Javier L. Muñoz, John F. Seymour, Stephen Opat
-
FBXO21 mediated degradation of p85α regulates proliferation and survival of acute myeloid leukemia Leukemia (IF 11.4) Pub Date : 2023-09-09 Kasidy K. Dobish, Karli J. Wittorf, Samantha A. Swenson, Dalton C. Bean, Catherine M. Gavile, Nicholas T. Woods, Gargi Ghosal, R. Katherine Hyde, Shannon M. Buckley
-
Reappraisal of mast cell leukemia based on a single institution review of 16 cases: Mast cell morphology determines clinical outcome Am. J. Hematol. (IF 12.8) Pub Date : 2023-09-09 Animesh Pardanani, Ayalew Tefferi, Aref Al-Kali, Mrinal Patnaik, William J. Hogan, Kebede Begna, Michelle A. Elliott, Nandita Khera, Jeanne M. Palmer, Naseema Gangat, Attilio Orazi, Katalin Kelemen, Kaaren K. Reichard, Dong Chen
-
Prospective analysis to determine barriers to allogeneic hematopoietic cell transplantation in patients with acute leukemia Am. J. Hematol. (IF 12.8) Pub Date : 2023-09-09 Karthik Nath, Jasme Lee, Theresa A. Elko, Lauren Levy, Elaina Preston, Sean M. Devlin, Doris M. Ponce, Richard J. Lin, Brian C. Shaffer, Christina Cho, Ioannis Politikos, Ann A. Jakubowski, Jae H. Park, Raajit Rampal, Miguel-Angel Perales, Martin S. Tallman, Juliet N. Barker, Ellin Berman, Roni Tamari, Eytan Stein, Sergio A. Giralt, Boglarka Gyurkocza
Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment for patients with acute leukemia. Despite this, studies have shown that only a minority of patients ultimately proceed to allo-HCT. The primary objective of this prospective, observational study was to identify the rate of allo-HCT in patients for whom it was recommended, and reasons why patients deemed appropriate
-
Effects of 2,3-DPG knockout on SCD phenotype in Townes SCD model mice Am. J. Hematol. (IF 12.8) Pub Date : 2023-09-09 Amey Barakat, Reema Jasuja, Lindsay Tomlinson, Zane Wenzel, Lila Ramaiah, Betty A. Petterson, Brendon Kapinos, Anagha Sawant, Vicente Pagan, Nathanael Lintner, Denise Field, Youngwook Ahn, Kelly M. Knee
Sickle cell disease (SCD) is a severe, multisystemic hematological disorder that impacts nearly every major organ in adults. The current approved treatments for SCD directly target mutant hemoglobin or address downstream disease pathology. Several compounds targeting reduction of 2,3-DPG by activation of Pyruvate Kinase-R are currently being evaluated in SCD patients. In this study, we genetically
-
Acute myeloid leukemia with mutated TP53: Is this newly proposed entity oversimplifying a complex group of neoplasms? Am. J. Hematol. (IF 12.8) Pub Date : 2023-09-08 Hong Fang, L. Jeffery Medeiros, Wei Wang
In the recently published International Consensus Classification (ICC) and the fifth edition of the World Health Organization classification on myeloid neoplasms,1, 2 the importance of TP53 mutation in disease pathogenesis and prognosis is recognized. The ICC goes a step further in recognizing acute myeloid leukemia (AML) with mutated TP53 as a separate distinct entity given that TP53 mutations are
-
Infection risk associated with clonal hematopoiesis of indeterminate potential is partly mediated by hematologic cancer transformation in the UK Biobank Leukemia (IF 11.4) Pub Date : 2023-09-09 Caitlyn Vlasschaert, Elvis Akwo, Cassianne Robinson-Cohen, Elina K. Cook, Matthew B. Lanktree, Michael J. Rauh, Alexander G. Bick
-
CT041 CAR T cell therapy for Claudin18.2-positive metastatic pancreatic cancer J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-09-09 Changsong Qi, Tong Xie, Jun Zhou, Xicheng Wang, Jifang Gong, Xiaotian Zhang, Jian Li, Jiajia Yuan, Chang Liu, Lin Shen
Pancreatic cancer lacks effective therapy. Here, we reported two metastatic pancreatic cancer patients administrated with Claudin 18.2 (CLDN 18.2) CART therapy after the failure of standard therapy (NCT04581473 and NCT03874897). In case 1, with CLDN 18.2 expression of 2+, 70%, 250 × 106 cells were infused after lymphodepletion. Grade 1 cytokine release syndrome (CRS) occurred on d1 which was later
-
Efficacy and safety of front-line treatment regimens for Waldenstrom macroglobulinaemia: a systematic review and meta-analysis Blood Cancer J. (IF 12.8) Pub Date : 2023-09-07 Wee-Lee Chan, Vanessa Cui Lian Chong, Ian Jun Yan Wee, Li Mei Poon, Esther Hian Lee Chan, Joanne Lee, Yen-Lin Chee, Anand D. Jeyasekharan, Wee-Joo Chng, Miny Samuel, Sanjay de Mel
-
Measurable residual disease monitoring in patients with acute myeloid leukemia treated with lower-intensity therapy: Roadmap from an ELN-DAVID expert panel Am. J. Hematol. (IF 12.8) Pub Date : 2023-09-06 Farhad Ravandi, Jacqueline Cloos, Francesco Buccisano, Richard Dillon, Konstanze Döhner, Sylvie D. Freeman, Christopher S. Hourigan, Gerrit J. Ossenkoppele, Gail J. Roboz, Marion Subklewe, Christian Thiede, Isabell Arnhardt, Peter J. M. Valk, Adriano Venditti, Andrew H. Wei, Roland B. Walter, Michael Heuser
With the availability of effective targeted agents, significant changes have occurred in the management of patients with acute myeloid leukemia (AML) over the past several years, particularly for those considered unfit for intensive chemotherapy. While testing for measurable residual disease (MRD) is now routinely performed in patients treated with intensive chemotherapy to refine prognosis and, possibly
-
Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European leukemia net risk classification Leukemia (IF 11.4) Pub Date : 2023-09-07 Jan-Niklas Eckardt, Marius Bill, Christian Rausch, Klaus Metzeler, Karsten Spiekermann, Sebastian Stasik, Tim Sauer, Sebastian Scholl, Andreas Hochhaus, Martina Crysandt, Tim H. Brümmendorf, Utz Krug, Bernhard Wörmann, Wolfgang Hiddemann, Dennis Görlich, Cristina Sauerland, Björn Steffen, Hermann Einsele, Andreas Neubauer, Andreas Burchert, Kerstin Schäfer-Eckart, Wolfgang E. Berdel, Christoph Schliemann
-
BRAFV600E promotes DC3/monocyte differentiation in human gene-engineered HSPCs and causes multisystem histiocytosis Leukemia (IF 11.4) Pub Date : 2023-09-06 Tommaso Sconocchia, Johannes Foßelteder, Lisa Auinger, Erdem Özkaya, Theresa Benezeder, Magdalena Lang, Christine Beham-Schmid, Gerald Hoefler, Armin Zebisch, Albert Wölfler, Heinz Sill, Peter Wolf, Herbert Strobl, Andreas Reinisch
-
PLK1 as a cooperating partner for BCL2-mediated antiapoptotic program in leukemia Blood Cancer J. (IF 12.8) Pub Date : 2023-09-07 Kinjal Shah, Ahmad Nasimian, Mehreen Ahmed, Lina Al Ashiri, Linn Denison, Wondossen Sime, Katerina Bendak, Iryna Kolosenko, Valentina Siino, Fredrik Levander, Caroline Palm-Apergi, Ramin Massoumi, Richard B. Lock, Julhash U. Kazi
-
Prospective evaluation of genome sequencing to compare conventional cytogenetics in acute myeloid leukemia Blood Cancer J. (IF 12.8) Pub Date : 2023-09-06 Beth A. Pitel, Cinthya Zepeda-Mendoza, Zohar Sachs, Hongwei Tang, Suganti Shivaram, Neeraj Sharma, James B. Smadbeck, Stephanie A. Smoley, Kathryn E. Pearce, Ivy M. Luoma, Joselle Cook, Mark R. Litzow, Nicole L. Hoppman, David Viswanatha, Xinjie Xu, Rhett P. Ketterling, Patricia T. Greipp, Jess F. Peterson, Linda B. Baughn
-
Clinical characteristics, genomic profiling and outcomes of single system multifocal Langerhans cell histiocytosis in adults with bone involvement Blood Cancer J. (IF 12.8) Pub Date : 2023-09-05 Hong-xiao Han, Long Chang, Min Lang, He Lin, Jian Li, Ming-hui Duan, Dao-bin Zhou, Xin-xin Cao
-
Second primary malignancies in patients with lymphoma in Denmark after high-dose chemotherapy and autologous haematopoietic stem-cell transplantation: a population-based, retrospective cohort study Lancet Haematol. (IF 24.7) Pub Date : 2023-09-06 Trine Trab, Joachim Baech, Lasse Hjort Jakobsen, Simon Husby, Marianne Tang Severinsen, Sandra Eloranta, Jette S Gørløv, Judit M Jørgensen, Sif Gudbrandsdottir, Thomas Stauffer Larsen, Peter Brown, Kirsten Grønbæk, Karin E Smedby, Tarec C El-Galaly
Background Second primary malignancies (SPMs) are known complications after chemotherapy, but the risk is not well characterised for patients with lymphoma treated with high-dose chemotherapy and autologous haematopoietic stem-cell transplantation (HSCT). We aimed to investigate the rate of SPMs in this population relative to matched control individuals from the general population. Methods In this
-
Correction to Lancet Haematol 2023; published online Aug 28. https://doi.org/10.1016/S2352-3026(23)00164-3 Lancet Haematol. (IF 24.7) Pub Date : 2023-09-06
Abstract not available
-
Beyond remission: secondary primary malignancies in patients with lymphoma after autologous haematopoietic stem-cell transplantation Lancet Haematol. (IF 24.7) Pub Date : 2023-09-06 Anna Sureda, Eva Domingo-Domenech
Abstract not available
-
A novel missense variant in ATP11C is associated with reduced red blood cell phosphatidylserine flippase activity and mild hereditary hemolytic anemia Am. J. Hematol. (IF 12.8) Pub Date : 2023-09-06 Myrthe J. van Dijk, Brigitte A. van Oirschot, Alexander N. Harrison, Steffen M. Recktenwald, Min Qiao, Amaury Stommen, Anne-Sophie Cloos, Juliette Vanderroost, Romano Terrasi, Kuntal Dey, Jennifer Bos, Minke A. E. Rab, Anna Bogdanova, Giampaolo Minetti, Giulio G. Muccioli, Donatienne Tyteca, Stéphane Egée, Lars Kaestner, Robert S. Molday, Eduard J. van Beers, Richard van Wijk
-
CAR virus receptor mediates erythroid differentiation and migration and is downregulated in MDS Leukemia (IF 11.4) Pub Date : 2023-09-06 Karin Bauer, Sigrid Machherndl-Spandl, Lukas Kazianka, Irina Sadovnik, Sinan Gültekin, Susanne Suessner, Johannes Proell, Jeroen Lauf, Gregor Hoermann, Gregor Eisenwort, Norman Häfner, Mathilde Födermayr-Mayrleitner, Ann-Sofie Schmolke, Emiel van der Kouwe, Uwe Platzbecker, Thomas Lion, Ansgar Weltermann, Otto Zach, Gerald Webersinke, Ulrich Germing, Christian Gabriel, Wolfgang R. Sperr, Marie C. Béné
-
MiR-9-1 controls osteoblastic regulation of lymphopoiesis Leukemia (IF 11.4) Pub Date : 2023-09-05 Yongguang Zhang, Danfeng Lin, Yongwei Zheng, Yuhong Chen, Mei Yu, Dongya Cui, Miaohui Huang, Xinlin Su, Yong Sun, Yabing Chen, Zhijian Qian, Karen-Sue Carlson, Renren Wen, Demin Wang
-
Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma Am. J. Hematol. (IF 12.8) Pub Date : 2023-09-05 Shin Yeu Ong, Stacy Pak, Matthew Mei, Yan Wang, Leslie Popplewell, John H. Baird, Alex F. Herrera, Geoffrey Shouse, Liana Nikolaenko, Jasmine Zain, James Godfrey, Myo Htut, Ahmed Aribi, Ricardo Spielberger, Joshua Mansour, Stephen J. Forman, Joycelynne Palmer, Lihua E. Budde
Fludarabine/cyclophosphamide (Flu/Cy) is established for lymphodepletion (LD) prior to standard-of-care CAR T-cell therapy for lymphoma. There is ongoing need to test alternative LD regimens to preserve efficacy, improve safety, and address challenges including the recent national fludarabine shortage. We retrospectively evaluated outcomes among patients with relapsed/refractory aggressive B-cell lymphoma
-
Long-term follow-up of tandem CD19/CD22 CAR T-Cells in r/r B-ALL patients with high-risk features Am. J. Hematol. (IF 12.8) Pub Date : 2023-09-04 Wei Cui, Xin-Yue Zhang, Zheng Li, Hai-Ping Dai, Jia Yin, Qing-Ya Cui, Si-Ning Liu, Li-Qing Kang, Lei Yu, De-Pei Wu, Xiao-Wen Tang
CD19 chimeric antigen receptor (CAR) T-cells therapy has shown remarkable therapeutic effect in treating relapsed and refractory B acute lymphoblastic leukemia (r/r B-ALL). However, approximately 50% of patients experience relapse within a year due to limited CAR T-cell persistence or CD19 antigen loss.1, 2 Dual-targeting approaches have demonstrated impressive antitumor activity.3 And it has been
-
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy J. Hematol. Oncol. (IF 28.5) Pub Date : 2023-09-05 Letong Cai, Yuchen Li, Jiaxiong Tan, Ling Xu, Yangqiu Li
In one decade, immunotherapy based on immune checkpoint blockades (ICBs) has become a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted therapies. However, not all cancer patients benefit from single or combination therapy with anti-CTLA-4 and anti-PD-1/PD-L1 monoclonal antibodies. Thus, an increasing number of immune checkpoint proteins (ICPs) have been screened
-
Clinical and immunological characteristics of prolonged SARS-CoV-2 Omicron infection in hematologic disease Blood Cancer J. (IF 12.8) Pub Date : 2023-09-05 Daisuke Ikeda, Ami Fukumoto, Yuka Uesugi, Rikako Tabata, Daisuke Miura, Kentaro Narita, Masami Takeuchi, Tomohisa Watari, Yoshihito Otsuka, Kosei Matsue
-
Cell-free DNA chromosome copy number variations predict outcomes in plasma cell myeloma Blood Cancer J. (IF 12.8) Pub Date : 2023-09-05 Wanting Qiang, Lina Jin, Tiancheng Luo, Yanchun Jia, Jing Lu, Jin Liu, Haiyan He, Ziliang Qian, Sridurga Mithraprabhu, Yang Liang, Robert Peter Gale, Xia Tao, Depei Wu, Juan Du